ArticleAmerican journal of translational research2025
Comprehensive exploration of signal sequence receptor subunit 1 (SSR1) as a diagnostic and prognostic biomarker in liver hepatocellular carcinoma.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The TRAP complex (SSR1-SSR4): mechanistic roles and therapeutic opportunities.Annals of medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study investigated the expression, clinical relevance, and functional role of signal sequence receptor 1 (SSR1) in liver hepatocellular carcinoma (LIHC). SSR1's potential as a diagnostic marker and its impact on tumor progression was assessed through multi-platform data analysis and in vitro functional assays. METHODOLOGY: Expression data from The Cancer Genome Atlas (TCGA), UALCAN, Oncomine, TIMER2.0, and Human Protein Atlas (HPA) were analyzed to assess SSR1 mRNA and protein expression in LIHC. Clinical correlations with tumor stage, race, gender, age, weight, and nodal metastasis were examined using UALCAN. Promoter methylation, mutation frequency, and prognostic significance were evaluated using UALCAN and OncoDB. Gene set enrichment analysis (GSEA) was conducted to identify pathways enriched in high SSR1 expression. Finally, real-time quantitative polymerase chain reaction (RT-qPCR), proliferation, colony formation, and wound healing assays were performed in QGY-7703 cell lines to validate the SSR1 function.
resultsSSR1 was significantly upregulated in LIHC tissues across multiple databases. Promoter hypomethylation was identified as a potential mechanism for this upregulation. High SSR1 expression correlated with worse overall survival and advanced tumor stages. Functional assays revealed that SSR1, SSR2, and SSR3 knockdown in LIHC cells significantly reduced cell proliferation and colony formation while enhancing migratory capacity.
conclusionSSR1 was overexpressed in LIHC and is associated with poor prognosis. It plays a critical role in promoting LIHC cell proliferation and survival, suggesting its potential as a diagnostic marker and therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.